File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ofloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis

TitleOfloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasis
Authors
Issue Date1989
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed
Citation
Respiratory Medicine, 1989, v. 83 n. 4, p. 299-303 How to Cite?
AbstractForty-one hospitalized adult patients of bronchiectasis (non-cystic fibrosis) with infective exacerbations were entered into a randomized, double-blind, placebo-controlled study comparing ofloxacin (200 mg tid) and amoxycillin (1 g tid) both orally for ten days. In the ofloxacin group (20 patients), improvement in sputum purulence was excellent in 14, and fair in five patients with one failure. In the amoxycillin group (21 patients), improvement in sputum purulence was excellent in eight, fair in five and poor in eight patients. Mean drug levels on day 5 were 4.1 mg l -1 for serum (2 h post-dosage) and 4.0 mg l -1 for sputum for ofloxacin, and 18.4 mg l -1 for serum and 0.3 mg l -1 for sputum for amoxycillin. Ofloxacin thus yielded higher sputum concentration and appeared to be more effective and also better tolerated than amoxycillin in infective episodes of bronchiectasis.
Persistent Identifierhttp://hdl.handle.net/10722/161787
ISSN
2015 Impact Factor: 3.036
2015 SCImago Journal Rankings: 1.396
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, WKen_US
dc.contributor.authorChau, PYen_US
dc.contributor.authorSo, SYen_US
dc.contributor.authorLeung, YKen_US
dc.contributor.authorChan, JCKen_US
dc.contributor.authorIp, Men_US
dc.contributor.authorSham, MKen_US
dc.date.accessioned2012-09-05T05:14:58Z-
dc.date.available2012-09-05T05:14:58Z-
dc.date.issued1989en_US
dc.identifier.citationRespiratory Medicine, 1989, v. 83 n. 4, p. 299-303en_US
dc.identifier.issn0954-6111en_US
dc.identifier.urihttp://hdl.handle.net/10722/161787-
dc.description.abstractForty-one hospitalized adult patients of bronchiectasis (non-cystic fibrosis) with infective exacerbations were entered into a randomized, double-blind, placebo-controlled study comparing ofloxacin (200 mg tid) and amoxycillin (1 g tid) both orally for ten days. In the ofloxacin group (20 patients), improvement in sputum purulence was excellent in 14, and fair in five patients with one failure. In the amoxycillin group (21 patients), improvement in sputum purulence was excellent in eight, fair in five and poor in eight patients. Mean drug levels on day 5 were 4.1 mg l -1 for serum (2 h post-dosage) and 4.0 mg l -1 for sputum for ofloxacin, and 18.4 mg l -1 for serum and 0.3 mg l -1 for sputum for amoxycillin. Ofloxacin thus yielded higher sputum concentration and appeared to be more effective and also better tolerated than amoxycillin in infective episodes of bronchiectasis.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmeden_US
dc.relation.ispartofRespiratory Medicineen_US
dc.subject.meshAdulten_US
dc.subject.meshAmoxicillin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshBacteria - Isolation & Purificationen_US
dc.subject.meshBacterial Infections - Drug Therapy - Microbiologyen_US
dc.subject.meshBronchiectasis - Drug Therapy - Microbiologyen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshOfloxacin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshSputum - Microbiologyen_US
dc.titleOfloxacin compared with amoxycillin in treating infective exacerbations in bronchiectasisen_US
dc.typeArticleen_US
dc.identifier.emailIp, M:msmip@hku.hken_US
dc.identifier.authorityIp, M=rp00347en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0954-6111(89)80200-8-
dc.identifier.pmid2692094-
dc.identifier.scopuseid_2-s2.0-0024434962en_US
dc.identifier.volume83en_US
dc.identifier.issue4en_US
dc.identifier.spage299en_US
dc.identifier.epage303en_US
dc.identifier.isiWOS:A1989AP01800008-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridChau, PY=36509704300en_US
dc.identifier.scopusauthoridSo, SY=7102397816en_US
dc.identifier.scopusauthoridLeung, YK=7201463867en_US
dc.identifier.scopusauthoridChan, JCK=23090202000en_US
dc.identifier.scopusauthoridIp, M=7102423259en_US
dc.identifier.scopusauthoridSham, MK=7003729112en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats